Surotomycin
Surotomycin is an investigational antibiotic that was under development by Cubist Pharmaceuticals, a subsidiary of Merck & Co.. It is a cyclic lipopeptide that was being developed for the treatment of Clostridium difficile infection (CDI). However, the development of Surotomycin was discontinued in 2016 after it failed to show superiority over vancomycin in Phase III clinical trials.
History[edit | edit source]
Surotomycin was first synthesized by Cubist Pharmaceuticals, a company known for its focus on research and development of antibiotics to treat serious infections. The development of Surotomycin was part of the company's efforts to combat the growing problem of antibiotic resistance.
In 2014, Cubist Pharmaceuticals was acquired by Merck & Co., a multinational pharmaceutical company. Following the acquisition, the development of Surotomycin continued under the new ownership.
Mechanism of Action[edit | edit source]
Surotomycin is a cyclic lipopeptide, a class of antibiotics that work by disrupting the bacterial cell membrane. It is bactericidal, meaning it kills bacteria rather than merely inhibiting their growth. Surotomycin specifically targets Clostridium difficile, a bacterium that can cause severe diarrhea and life-threatening inflammation of the colon.
Clinical Trials[edit | edit source]
Surotomycin underwent Phase I, II, and III clinical trials. The Phase III trials, however, did not show Surotomycin to be superior to vancomycin, a currently used treatment for CDI. As a result, Merck & Co. decided to discontinue the development of Surotomycin in 2016.
Future[edit | edit source]
Despite the discontinuation of Surotomycin, research into new treatments for CDI continues. The failure of Surotomycin underscores the challenges of developing new antibiotics and the importance of ongoing research in this area.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
